Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 23;78(Suppl 2):ii37-ii42.
doi: 10.1093/jac/dkad314.

COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance

Sabine Bou-Antoun  1 , Sakib Rokadiya  2 , Diane Ashiru-Oredope  1 , Alicia Demirjian  1   3   4 , Emma Sherwood  5 , Nicholas Ellaby  2 , Sarah Gerver  1 , Carlota Grossi  6 , Katie Harman  7 , Hassan Hartman  2 , Alessandra Lochen  8 , Manon Ragonnet-Cronin  2   9   10 , Hanna Squire  1 , J Mark Sutton  11   12 , Simon Thelwall  7 , Julia Tree  11 , Mohammad W Bahar  13 , David I Stuart  13   14 , Colin S Brown  1 , Meera Chand  2 , Susan Hopkins  1
Affiliations

COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance

Sabine Bou-Antoun et al. J Antimicrob Chemother. .

Abstract

The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.

PubMed Disclaimer

Conflict of interest statement

This supplementary publication is being supported by funding from Roche; Roche have had no influence on the contents of this manuscript. D.I.S. consults for AstraZeneca.

Figures

Figure 1.
Figure 1.
Overview of in vitro method (using VeroE6 cells). This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
See this image and copyright information in PMC

References

    1. O'Neill J. Review on Antimicrobial Resistance Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Ta...
    1. Mendelson M, Sharland M, Mpundu M. Antibiotic resistance: calling time on the ‘silent pandemic’. JAC Antimicrob Resist 2022; 4: dlac016. 10.1093/jacamr/dlac016 - DOI - PMC - PubMed
    1. Horby PBW, Hiscox J, Chand M. et al. et al. New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG): Antiviral drug resistance and the use of directly acting antiviral drugs 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploa...
    1. Rockett R, Basile K, Maddocks Set al. . Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use. N Engl J Med 2022; 386: 1477–9. 10.1056/NEJMc2120219 - DOI - PMC - PubMed
    1. Medicines and Healthcare Products Regulatory Agency (MHRA) . Coronavirus (COVID-19) Alerts: COVID-19 therapeutic access policies, central alert system (CAS alerts). https://www.cas.mhra.gov.uk/Help/CoronavirusAlerts.aspx

Publication types